New Australian study below [1].
Seems a long time coming. ("6-month randomised, placebo-controlled trial")
"In men, many effects of testosterone (T) on the skeleton are thought to be mediated by estradiol (E2), but trial evidence is largely lacking."
"Relative to placebo, E2 treatment increases some measures of bone density and bone strength in men and reduces bone remodelling, effects that occur in absence of endogenous T."
Therefore, E2 replacement should occur, if necessary, before bisphosphonates, etc, be resorted to.
IMO, target E2 is 20 pg/mL when E2 is <12 pg/mL. Using the lowest dose E2 patch.
-Patrick
[1] pubmed.ncbi.nlm.nih.gov/356...
Eur J Endocrinol
. 2022 Jun 1;EJE-22-0227. doi: 10.1530/EJE-22-0227. Online ahead of print.
Effects of estradiol on bone in men undergoing androgen deprivation therapy: a randomised placebo-controlled trial
Nicholas Russell 1 , Ali Ghasem-Zadeh 2 , Rudolf Hoermann 3 , Ada S Cheung 4 , Jeffrey D Zajac 5 , Cat Shore-Lorenti 6 , Peter R Ebeling 7 , David J Handelsman 8 , Mathis Grossmann 9
Affiliations collapse
Affiliations
1 N Russell, Department of Endocrinology, Austin Health, Heidelberg, 3084, Australia.
2 A Ghasem-Zadeh, Department of Endocrinology, Austin Health, Heidelberg, Australia.
3 R Hoermann, Department of Medicine (Austin Health), The University of Melbourne Department of Medicine Austin Health, Heidelberg, Australia.
4 A Cheung, Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Australia.
5 J Zajac, Medicine, University of Melbourne, Heidelberg, Australia.
6 C Shore-Lorenti, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.
7 P Ebeling, Medicine, Monash University, Clayton, Australia.
8 D Handelsman, ANZAC Research Institute and Dept of Andrology, Dept of Andrology, Sydney, Australia.
9 M Grossmann, Medicine, Austin Health/ Northern Health, University of Melbourne, Heidelberg, Australia.
PMID: 35666800 DOI: 10.1530/EJE-22-0227
Abstract
Objective: In men, many effects of testosterone (T) on the skeleton are thought to be mediated by estradiol (E2), but trial evidence is largely lacking. This study aimed to determine the effects of E2 on bone health in men in the absence of endogenous T.
Design: 6-month randomised, placebo-controlled trial with the hypothesis that E2 would slow decline of volumetric bone mineral density (vBMD) and bone microstructure, maintain areal bone mineral density (aBMD), and reduce bone remodelling.
Methods: 78 participants receiving androgen deprivation therapy for prostate cancer were randomised to 0.9mg of 0.1% E2 gel daily, or matched placebo. The outcome measures were vBMD and microarchitecture at the distal tibia and distal radius by high-resolution peripheral quantitative CT, aBMD at the spine and hip by dual energy x-ray absorptiometry, and serum bone remodelling markers.
Results: For the primary endpoint, total vBMD at the distal tibia, there was no significant difference between groups, mean adjusted difference (MAD) 2.0mgHA/cm3 (95%CI -0.8 - 4.8), p=0.17. Cortical vBMD at the distal radius increased in the E2 group relative to placebo, MAD 14.8mgHA/cm3 (95%CI 4.5-25.0), p=0.005. Relative to placebo, E2 increased estimated failure load at tibia, MAD 250N (95%CI 36-465), p=0.02 and radius, MAD 193N (95%CI 65-320), p=0.003. Relative to placebo, E2 increased aBMD at the lumbar spine, MAD 0.02g/cm2 (95%CI 0.01-0.03), p=0.01, and ultra-distal radius, MAD 0.01g/cm2 (95%CI 0.00 - 0.02), p=0.01, and reduced serum bone remodelling markers.
Conclusion: Relative to placebo, E2 treatment increases some measures of bone density and bone strength in men and reduces bone remodelling, effects that occur in absence of endogenous T.